You are here

  • Home
  • Archive
  • Volume 46, Issue 11
  • Characterisation of psoriasis susceptibility locus 6 (PSORS6) in patients with early onset psoriasis and evidence for interaction with PSORS1

Article Text

Article menu
Original article
Characterisation of psoriasis susceptibility locus 6 (PSORS6) in patients with early onset psoriasis and evidence for interaction with PSORS1
  1. U Hüffmeier1,
  2. J Lascorz1,
  3. T Becker2,
  4. F Schürmeier-Horst3,
  5. A Magener4,
  6. A B Ekici1,
  7. S Endele1,
  8. C T Thiel1,
  9. S Thoma-Uszynski5,
  10. R Mössner6,
  11. K Reich7,
  12. W Kurrat8,
  13. T F Wienker2,
  14. H Traupe5,
  15. A Reis1
  1. 1
    Institute of Human Genetics, University Hospital Erlangen, University Erlangen-Nuremberg, Germany
  2. 2
    Institute of Medical Biometry, Informatics and Epidemiology, University of Bonn, Germany
  3. 3
    Department of Dermatology, University of Münster, Germany
  4. 4
    Department of Pathology, University of Erlangen, Germany
  5. 5
    Department of Dermatology, University of Erlangen, Germany
  6. 6
    Department of Dermatology, University of Göttingen, Germany
  7. 7
    Dermatologikum Hamburg, Hamburg, Germany
  8. 8
    Asklepios Nordseeklinik, Westerland/Sylt, Germany
  1. Correspondence to Professor A Reis, Institute of Human Genetics, University Hospital Erlangen, University of Erlangen-Nuremberg, 91054 Erlangen, Germany; reis{at}humgenet.uni-erlangen.de

Abstract

Background: Psoriasis is a genetically complex, chronic inflammatory skin disease. The authors have previously identified a susceptibility locus on chromosome 19p13 (PSORS6).

Methods and results: In a follow-up linkage disequilibrium (LD) study in an independent family based cohort, the authors found evidence for association to a newly discovered microsatellite at this locus (D19SPS21, p<5.3×10−5). An LD based association scan in 300 trios revealed association to several single, single nucleotide polymorphisms (SNPs) in one LD block. When the authors stratified this cohort for carrying the PSORS1 risk allele at the HLA-C locus, evidence for association became much stronger at single SNP and haplotype levels (p values between 1.0×10−4 and 8.0×10−4). In a replication study of 1114 patients and 937 control individuals, evidence for association was also observed after stratification to the PSORS1 risk allele. In both study groups, logistic regression showed evidence for interaction between the risk alleles at PSORS1 and PSORS6. Best p values for rs12459358 in both study groups remained significant after correction for multiple testing. The associated LD block did not comprise any known genes. Interestingly, an adjacent gene, MUC16, coding for a large glycosylated protein expressed in epithelia and of unknown function, could be shown to be also expressed in tissues relevant for pathogenesis of psoriasis such as skin and thymus. Immunohistochemical analyses of skin revealed focal staining for MUC16 in suprabasal epidermal cells. Further functional studies are required to clarify its potential role in psoriasis and identify the causal variant(s) at this locus.

Conclusion: The data establish PSORS6 as a confirmed psoriasis susceptibility locus showing interaction with PSORS1.

https://doi.org/10.1136/jmg.2008.065029

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Supplementary materials

    Footnotes

    • ▸ Additional tables and figure are published online only at http://jmg.bmj.com/content/vol46/issue11

    • Funding This work was supported by grants from the Deutsche Forschungsgemeinschaft (DFG, Tr 228/5-4 and Re 679/10-4) and by a grant from the Interdisciplinary Centre for Clinical Research (IZKF B32/A8) of the University of Erlangen-Nuremberg.

    • Competing interests None.

    • Ethics approval The studies were approved by the ethical committees of the University of Erlangen-Nuremberg and of the University of Münster

    • Patient consent Obtained.

    • Provenance and Peer review Not commissioned; externally peer reviewed.